|
KMID : 0606920070150010001
|
|
Biomolecules & Therapeutics
2007 Volume.15 No. 1 p.1 ~ p.6
|
|
|
Progress in the Direct Application of Pharmacogenomics to Patient Care: Sustaining innovation
|
|
Burckart Gilbert J.
Frueh Felix W.
Lesko Lawrence J.
|
|
|
Abstract
|
|
|
|
The application of the knowledge from the Human Genome Project to clinical medicine will be through both industrial drug development and the application of pharmacogenomics (PG) to patient care. The slow uptake of clinical innovations into clinical practice can be frustrating, but understanding the history of acceptance and sustaining medical innovation is critically important to position PG to succeed. This primarily means that PG tests must have legitimacy; they must be thoroughly validated, must be cost-effective, must be widely accepted by medical practitioners, must be supported by public policy, and must have a way of being easily incorporated into current medical practice. They must also lead to actionalble decisions by health care providers for their patients. Innovative PG assays should be tested in the best US laboratories, and reimbursement for testing must be accepted at the federal and state level. The companies providing these PG tests should be capable of sup-porting the interpretation and use of the test throughout medical practice. Advances such as the addition of PG information to drug labeling and the routine use of validated biomarkers to determine choice of cancer chemotherapy have been made. The PG research community must pay attention to the principles that have been previously described for acceptance and sustaining medical innovations in order for PG to be widely accepted in clinical medical practice
|
|
|
KEYWORD
|
|
|
pharmacogenomics, patient care, biomarkers, PG testing
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|